B. Riley lowered the firm’s price target on Harrow Health to $30 from $45 and keeps a Buy rating on the shares. The analyst views the lower than expected Q4 outlook as disappointing but says Iheezo trends are the “silver lining.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HROW: